Statistical methods in cancer research

Journal of Surgical Oncology

Volumn 76, Issue 3, 2001, Pages 201-223

  Polgár, Csaba ^a   Orosz, Zsolt ^a   Fodor, János ^a   Majeski, James ^b  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; DATA ANALYSIS; METHODOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 0035086280     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.1035     Document Type: Review

References (151)

1. How to report randomized controlled trials. The CONSORT statement
2. Improving the quality of reporting of randomized controlled trials. The CONSORT statement
3. Basic principles in designing and analyzing clinical studies
4. Factors often not considered before a multicenter trial is started
5. Statistical concepts fundamental to investigations
6. How to do a simple epidemiological study. I. Planning
7. Guidelines for statistical reporting in articles for medical journals
8. Assessing the direction of causality in cross-sectional studies
9. Causality inference in observational vs experimental studies. An empirical comparison
10. Statistics in practice. Designs for experiments: Parallel comparisons of treatment
11. Statistics in practice. A classification for biomedical research reports
12. Pharmacokinetic evaluation of stable piecewise cubic polynomials as numerical integration functions
13. Science, statistics, and deception
14. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
15. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
16. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The America College of Physicians
17. Risk biomarkers and current strategies for cancer chemoprevention
18. Perspective: Validating surrogatemarkers - Are we being naive?
19. Surrogate endpoints
20. Estimating the proportion of treatment effect explained by a surrogate marker
21. Surrogate end points in cancer research: A critique
22. Design of the prostate cancer prevention trial (PCPT)
23. Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy
24. A new short form individual quality of life measure (SEIQoL-DW): Application in a cohort of individuals with HIV/AIDS
25. An overview of generic health-related quality of life measures for HIV research
26. Treatment helpfulness questionnaire: A measure of patient satisfaction with treatment modalities provided in chronic pain management programs
27. Building quality of life assessment into cancer treatment studies
28. "Cancer clinical trials. Methods and practice." Evaluating "quality of life"
29. Is there a role for preference assessments in research on quality of life in oncology?
30. Measuring health-related quality of life
31. Quality of health care. Part 1: Quality of care - What Is It?
32. The need for endpoints in anticancer drug trials that will simplify the clinical decision-making process
33. Assessing quality of life in comparative cancer clinical trials: Does it make a difference?
34. Does assessment of quality of life in comparative cancer trials make a difference? A discussion
35. Do quality of life assessments make a difference in the evaluation of cancer treatments?
36. The clinical-economic trial: Promise, problems, and challenges
37. Variations in breast cancer treatment decisions and their impact in mounting trials
38. Randomized clinical trials in oncology. Principles and obstacles
39. Cost efficiency in study planning and completion. How many cases? How many controls?
40. Optimal sampling strategies for two-stage studies
41. Negative studies
42. Why isn't everyone a bayesian (with comments)?
43. Advances in data assessment
44. Statistical analysis in the computer age
45. An analysis of two recent epidemiological reports in the New England journal of medicine associating breast cancer in women with moderate alcohol consumption
46. Influence of study goals on study design and execution
47. Using a community clinical trials network for treatment, prevention, and control research: Assuring access to state-of-the-art cancer care
48. Introduction to the American cancer society national conference on clinical trials
49. Some problems with clinical trials
50. Bias
51. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
52. Estimating efficacy from clinical trials
53. Annotation: What can be done about missing data? Approaches to imputation
54. Advances in strategies for minimizing and adjusting for survey nonresponse
55. Multiple imputation in health-care databases: An overview and some applications
56. Determining sample sizes for clinical trials
57. Anscombe GEM: Sins of omission? The non-treatment of controls in clinical trials. II
58. Clinical trials-are they ethical?
59. Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer
60. Cutoff assignment strategies for enhancing randomized clinical trials
61. Sample sizes for group sequential cohort and case control study designs
62. The Holy Bible
63. An important role for epidemiologists: Improving administrative databases
64. The box plot: A simple visual method to interpret data
65. Interpretation of survival data in clinical trials
66. Adjusting survival curves for confounders: A review and a new method
67. Trees and splines in survival analysis
68. Flexible covariate effects in the proportional hazards model
69. A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer
70. Heterogeneity in survival analysis
71. 5-Year cure rate: Yet another myth
72. Viewpoints and concerns of a clinical trial participant
73. Clinical trial participation. Viewpoints from racial/ethnic groups
74. Special aspects of cancer prevention trials
75. Barriers to clinical trials. Part I: Reimbursement problems
76. Behavioral aspects of clinical trials. An integrated framework from behavior theory
77. Recruitment for controlled clinical trials: Literature summary and annotated bibliography
78. Participants' perceptions of a phase I colon cancer chemoprevention trial
79. Failure to comply: A therapeutic dilemma and the bane of clinical trials
80. Analyzing non-compliance in clinical trials: Ethical imperative or mission impossible?
81. Confirmatory analysis of survival data using left truncation of the life times of primary survivors
82. Global tests for multiple binary outcomes
83. Use of a global test for mutiple outcomes in stroke trials with application to the national institute of neurological disorders and stroke 5-PA stroke trial
84. Interpreting tests for efficacy in clinical trials with multiple endpoints
85. Some statistical methods for multiple endpoints in clinical trials
86. Interim analyses in clinical trials
87. Bonferroni sometimes loses
88. Adjusting for multiple testing when reporting research results: The bonferroni vs holm methods
89. Annotation: On the holm, simes, and hochberg multiple test procedures
90. Sample size tables for logistic regression
91. A user's review of commercial sample size software for design of biomedical studies using survival data
92. Confidence intervals in research evaluation
93. Basic statistics for clinicians: 2. Interpreting study results: Confidence intervals
94. Calculating confidence intervals for relative risks (Odds Ratios) and standardised ratios and rates
95. Confidence intervals rather than P values: Estimation rather than hypothesis testing
96. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results
97. Non-linear models for the analysis of longitudinal data
98. Analysis of growth and dose response curves
99. The future of prognostic factors in outcome prediction for patients with cancer
100. Criteria for prognostic factors and for an enhanced prognostic system
101. Why do so many prognostic factors fail to pan out?
102. Prognostic trees to aid prognosis in patients with cutaneous malignant melanoma
103. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials
104. An empirical comparison of expert-derived and data-derived classification trees
105. Computer modeling and decision making: Clinical applications in bladder cancer
106. Cost-effectiveness in the post-treatment follow-up of cancer patients
107. The measurement of the value of the clinical process to the individual by age and income
108. The relation of "human capital" preservation to health costs
109. The physician's role in minimizing the economic morbidity of cancer
110. The decision-making process in cancer patient care
111. Effects of outcome framing on treatment decisions in the real world: Impact of framing on adjuvant breast cancer decisions
112. Whose utilities for decision analysis?
113. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer
114. Obstacles to acceptance of clinical decision analysis
115. Application of decision to treatment choices: Implications for the design and analysis of clinical trials
116. Increasing the power of clinical trials through judgement analysis
117. Meta-analysis in the breech
118. Review of developments in meta-analytic method
119. Commentary
120. Meta-analysis of observational epidemiological studies: A review
121. Meta-analysis software: A comparative review
122. Methodologic guidelines for reports of clinical trials